Diagnosis & Differentiation
Analysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma
Cancers 2025 January 14 [Link] Antonio d’Amati, Gabriella Serio, Andrea Quaranta, Luigi Vimercati, Michelina De Giorgis, Loredana Lorusso, Mariella Errede, Vito Longo, Andrea Marzullo, Domenico Ribatti, Tiziana Annese Abstract Background/objectives: Telomerase reverse transcriptase (TERT) is the catalytic subunit of the telomerase enzyme responsible for telomere length maintenance and is an important cancer hallmark. Our study…
Read MoreCase report: Radiological features of a case of desmoplastic malignant mesothelioma of peritoneum
Frontiers in Oncology 2024 December 11 [Link] Jingchao Wang, Heping Deng Abstract Desmoplastic malignant peritoneal mesothelioma (DMPM) is an extremely rare and aggressive subtype of sarcomatoid malignant mesothelioma, originating from the mesothelial lining of body cavities. It is characterized by significant local invasiveness and poor prognosis. The nonspecific symptoms of DMPM often result in delayed…
Read MoreAmerican Association of Bronchology and Interventional Pulmonology Essential Knowledge in Interventional Pulmonology Series: Selected Topics in Malignant Pleural Disease
Journal of Bronchology and Interventional Pulmonology 2024 December 20 [Link] Ara A Chrissian, Hatoon Abbas, Udit Chaddha, Labib G Debiane, Erin DeBiasi, Darius Filsoof, Muhammad Daniyal Hashmi, Christopher Morton, Warren C Naselsky, Jasleen Pannu, Reza Ronaghi, Bertin D Salguero, Cristina Salmon, Shelby J Stewart, Colleen L Channick Abstract The goal of the American Association of…
Read MoreTEAD-independent cell growth of Hippo-inactive mesothelioma cells: Unveiling resistance to TEAD inhibitor K-975 through MYC signaling activation
Molecular Cancer Therapeutics 2024 December 17 [Link] Ken Akao, Tatsuhiro Sato, Emi Mishiro-Sato, Satomi Mukai, Farhana Ishrat Ghani, Lisa Kondo-Ida, Kazuyoshi Imaizumi, Yoshitaka Sekido Abstract Inactivation of the Hippo tumor suppressive pathway is frequently observed in mesothelioma, which leads to the activation of YAP and TAZ (YAP/TAZ) transcriptional coactivators. YAP/TAZ form complexes with TEAD family…
Read MoreSerum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma
Frontiers in Immunology 2024 December 2 [Link] Saima Jamil Farooqi, Zhi Zhao, Åsa Kristina Öjlert, Solfrid Thunold, Hedvig Vidarsdotter Juul, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Hanne Marte Gjertsen Nymoen, Åslaug Helland, Vilde Drageset Haakensen Abstract Background: Pleural mesothelioma (PM) is a rare cancer with a dismal prognosis. Dual immune checkpoint inhibitors have improved overall survival,…
Read MoreRole of Immunocytochemistry in the Cytological Diagnosis of Mesothelioma
Acta Cytologica 2024 December 12 [Link] Claire W Michael, Shannon Alexandra Rodgers Abstract Background: Mesothelioma is an aggressive malignancy of the serosal surfaces with very poor prognosis. It traditionally manifests in older patients and at an advanced stage which results in minimal improvement in prognosis despite the recent advances in management. Early detection would therefore…
Read MoreThe prevalence and prognostic significance of Sarcopenia and Adipopenia in Pleural Mesothelioma
Cancer Treatment and Research Communications 2024 [Link] Andrew C Kidd, Gordon W Cowell, Geoffrey A Martin, Jenny Ferguson, Dean A Fennell, Matt Evison, Kevin G Blyth Abstract Introduction: Altered body composition is associated with adverse survival in multiple cancers. We determined the prevalence, prognostic significance and clinicopathological correlates of sarcopenia and adipopenia in Pleural Mesothelioma…
Read MoreEpithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report
General Thoracic Cardiovascular Surgical Cases 2024 June 11 [Link] Gaku Yamazaki, Aki Fujiwara-Kuroda, Jun Muto, Hideki Ujiie, Masato Aragaki, Megumi Furuta, Sakurako Ohno, Kanako C Hatanaka, Yutaka Hatanaka, Yoshihiro Matsuno, Tatsuya Kato Abstract Background: Pleural mesothelioma, characterized by a dismal prognosis even with multimodal therapy, has seen emerging interest in immune checkpoint inhibitors (ICIs) due…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 204 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read MoreBiomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)
Oncology Letters 2024 October 9 [Link] Chunhong Wang, Yan Zhao, Wanru Liang Abstract Malignant peritoneal mesothelioma (MPeM) is a type of rare and highly lethal tumor. Immune checkpoint blockade (ICB)-based therapy has shown encouraging clinical activity for MPeM. However, no definitive biomarkers have been identified for predicting which patients with MPeM will benefit from ICB-based…
Read More
Skip to content